Amylyx reports Q4 net loss of $37.5M, cash runway extended through 2026 after $65.5M raise

Amylyx Pharmaceuticals, Inc.

Net loss for Q4 2024 was $37.5M ($0.55 per share); FY2024 net loss of $301.7M ($4.43 per share).
Cash, equivalents & short-term investments were $176.5M at Dec 31, 2024; plus $65.5M raised in Jan 2025.
Phase 3 LUCIDITY trial of avexitide in PBH recruiting; topline data expected first half 2026.
Appointed Dan Monahan as Chief Commercial Officer to lead commercialization strategy.
R&D expenses fell to $22.9M in Q4 2024 from $44.9M in Q4 2023; SG&A fell to $17.1M from $52.2M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.